Bristol Myers Squibb reports Sotyktu trial results

• Bristol Myers Squibb (NYSE:BMY) reported two-year Phase 3 POETYK PsA-2 results showing continued efficacy for Sotyktu in adults with active psoriatic arthritis.
• Sotyktu maintained responses through Week 104 across ACR20/50/70 and Minimal Disease Activity measures.
• The company reported no new safety signals during the two-year treatment period.

Bristol Myers Squibb (NYSE:BMY) reported positive two-year results from the Phase 3 POETYK PsA-2 study and its open-label extension, showing continued efficacy and a consistent safety profile for Sotyktu (deucravacitinib) in adults with active psoriatic arthritis.

The results showed that patients receiving continuous Sotyktu treatment achieved ACR20/50/70 response rates of 76.2%, 52.6% and 34.6%, respectively, at Week 104 based on observed analysis.

“Following the approval of Sotyktu for adults with active psoriatic arthritis, these results through two years of treatment reinforce the durable efficacy and safety profile observed across our clinical program,” said Liz Colston, MD, PhD, Vice President and Head of Immunology Development, Bristol Myers Squibb.

Patients who switched from placebo to Sotyktu at Week 16 also maintained responses through Week 104, with observed ACR20/50/70 response rates of 76.9%, 54.6% and 37.7%, while safety results showed adverse events in 86.6% of 604 patients and no new safety signals.

Bristol Myers Squibb develops medicines across areas including immunology, oncology, cardiovascular disease and other therapeutic categories, with Sotyktu being evaluated across immune-mediated conditions.

The POETYK PsA-2 trial evaluated Sotyktu in 729 adults with active psoriatic arthritis, including patients who had not previously received biologic disease-modifying antirheumatic drugs and those with prior TNFα inhibitor treatment, with open-label extension treatment continuing through Week 156.